A pathogenic mutation of hereditary central halo retinopathy and its detection reagent

A retinopathy and hereditary technology, applied in the field of the pathogenic mutation of hereditary central halo retinopathy and its detection reagent, can solve the problems of unreported, cone and rod dystrophy, cone cell degeneration, etc.

Inactive Publication Date: 2019-03-15
JIANGSU PROVINCE HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The Guanylyl cyclase-activating protein 1 (GUCA1A; MIM 600364) gene is located at position 6p21.1 on the short arm of chromosome 6. The gene contains 6 exons, and the GCAP 1 protein encoded by it is a retina-specific protein containing 201 amino acids. It is reported that the GUCA1A gene mutation can cause cone cell degeneration and cone-rod cell dystrophy, but the relationship between it and CACD has not been reported at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pathogenic mutation of hereditary central halo retinopathy and its detection reagent
  • A pathogenic mutation of hereditary central halo retinopathy and its detection reagent
  • A pathogenic mutation of hereditary central halo retinopathy and its detection reagent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] A five-generation family with central areolar choroidal dystrophy (CACD) was tested for GUCA1A mutations.

[0050] experimental method:

[0051] 1. Collection of clinical resources of the family and establishment of a genetic resource bank:

[0052] The clinical data and blood samples of each member of the family were collected, see the family diagram figure 1 . Clinical data mainly include personal medical history, family history, best corrected visual acuities (BCVAs), slit lamp examination, fundus photography, color vision examination, visual field examination (Humphrey perimetry), visual evoked potential detection (visual-evokedpotentials); VEP), full field electrophysiology (electroretinography; ERG), fundus fluoresceinangiography (FFA) and optical coherence tomography (optical coherencetomography; OCT), etc. The blood genomic DNA of each family member was extracted with a blood genomic DNA extraction kit (Qiagen, Hilden, Germany).

[0053] 2. Discover the path...

Embodiment 2

[0083] A functional study was conducted on the pathogenic mutation GUCA1A p.Arg120Leu detected in Example 1.

[0084] experimental method:

[0085] 1. Conservative analysis:

[0086] The NCBI HomoloGene database (http: / / www.ncbi.nlm.nih.gov / homologene) was used to evaluate and predict the conservation of the screened mutations in multiple species.

[0087] 2. Research on protein crystal structure changes:

[0088] SWISS MODEL (http: / / swissmodel.expasy.org / ) prediction software was used to predict the structure of GUCA1A wild-type protein and the mutant protein carrying the p.Arg120Leu mutation, and evaluate the protein structure changes caused by the mutation.

[0089] 3. Zebrafish experiment:

[0090] Synthesize the full-length cDNA of wild type and mutant human GUCA1A gene respectively and clone it into pxT7 vector to construct pxT7 tagged GUCA1A WT and GUCA1A MU Plasmids from which to synthesize the corresponding GUCA1A mRNA, including GUCA1A WT and GUCA1A MU mRNA. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pathogenic mutant gene of hereditary central areolar retinopathy and a detection reagent thereof. The pathogenic mutant gene is a GUCA1A gene used for detecting hereditary central areolar retinopathy, and the mutant GUCA1A gene is heterozygously mutant GUCA1A p.Arg120Leu. Further disclosed is a kit for detecting hereditary central areolar retinopathy. The kit comprises a reagent for detecting nucleotide sites with physical positions of 42146547 and 42146548 of the GUCA1A gene, or a reagent for detecting 120th amino acid site of GCAP 1 protein (a) and a specification (b). Hereditary central areolar retinopathy can be diagnosed by detecting the mutant GUCA1A gene.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a pathogenic mutation of hereditary central halo retinopathy and a detection reagent thereof. Background technique [0002] Central areolar choroidal dystrophy (CACD) is a group of progressive retinal degenerative diseases caused by genetic defects, such diseases are mainly caused by the irreversible atrophy of retinal pigment epithelium (RPE) and choroidal blood vessels pathological features. CACD patients mainly harm the macular area of ​​the patient, causing a progressive decline in central vision, and severe cases can cause blindness. CACD is a clinically common and serious hereditary blinding disease, which can be divided into four stages according to its clinical features. Early CACD patients are difficult to make an accurate clinical diagnosis because their phenotypes are easily confused with other fundus disease patients. Therefore, it is particularly important to find other po...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/12C07K14/47C12Q1/6883G01N33/68
CPCC07K14/47C12Q1/6883C12Q2600/156G01N33/68G01N2333/47G01N2800/164
Inventor 赵晨陈雪
Owner JIANGSU PROVINCE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap